Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry.
暂无分享,去创建一个
R. Manna | A. Renieri | R. Cimaz | A. Vitale | Claudia Fabiani | G. Emmi | G. Lopalco | B. Frediani | D. Rigante | G. Ragab | A. Cauli | J. Hernández-Rodríguez | L. L. Sicignano | E. Verrecchia | M. Maggio | E. Więsik-Szewczyk | M. Frassi | P. Parronchi | C. Gaggiano | M. Cattalini | J. Sota | C. Luca | E. Aragona | Vittoria Lamacchia | M. Tarsia | M. Mourabi
[1] P. Nigrovic,et al. Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach. , 2020, The Journal of allergy and clinical immunology.
[2] R. Gautam,et al. Systematic literature review of efficacy/effectiveness and safety of current therapies for the treatment of cryopyrin-associated periodic syndrome, hyperimmunoglobulin D syndrome and tumour necrosis factor receptor-associated periodic syndrome , 2020, RMD Open.
[3] R. Gautam,et al. A systematic literature review of efficacy, effectiveness and safety of biologic therapies for treatment of familial Mediterranean fever. , 2020, Rheumatology.
[4] A. Renieri,et al. Hints for Genetic and Clinical Differentiation of Adult-Onset Monogenic Autoinflammatory Diseases , 2019, Mediators of inflammation.
[5] R. Manna,et al. Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease , 2019, Front. Pharmacol..
[6] N. Kutukculer,et al. Successful management of colchicine resistant familial Mediterranean fever patients with a standardized canakinumab treatment protocol: a case series and literature review , 2019, Rheumatology International.
[7] M. Sormani,et al. Classification criteria for autoinflammatory recurrent fevers , 2019, Annals of the rheumatic diseases.
[8] H. Ozdogan,et al. Familial Mediterranean Fever. , 2019, Presse medicale.
[9] R. Cimaz,et al. Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis , 2019, Front. Pharmacol..
[10] B. Makay,et al. Long-term effectiveness and safety of canakinumab in pediatric familial Mediterranean fever patients , 2020, Modern rheumatology.
[11] G. Cavalli,et al. Anakinra Therapy for Non-cancer Inflammatory Diseases , 2018, Front. Pharmacol..
[12] B. Goker,et al. On demand use of anakinra for attacks of familial Mediterranean fever (FMF) , 2018, Clinical Rheumatology.
[13] E. Ben-Chetrit,et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes , 2018, The New England journal of medicine.
[14] A. Vaglio,et al. Monogenic Autoinflammatory Diseases with Mendelian Inheritance: Genes, Mutations, and Genotype/Phenotype Correlations , 2017, Front. Immunol..
[15] I. Ben-Zvi,et al. Anakinra for Colchicine‐Resistant Familial Mediterranean Fever: A Randomized, Double‐Blind, Placebo‐Controlled Trial , 2017, Arthritis & rheumatology.
[16] D. Rigante. A systematic approach to autoinflammatory syndromes: a spelling booklet for the beginner , 2017, Expert review of clinical immunology.
[17] A. Martini,et al. Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study , 2016, Annals of the rheumatic diseases.
[18] H. Takada,et al. Long-term safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: results from an open-label, phase III pivotal study in Japanese patients. , 2017, Clinical and experimental rheumatology.
[19] L. Punzi,et al. A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study , 2016, Front. Pharmacol..
[20] M. McDermott,et al. Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology. , 2016, JCI insight.
[21] H. Olivecrona,et al. Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes , 2016, Rheumatology.
[22] N. Blank,et al. Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome. , 2016, Rheumatology.
[23] S. Ozen,et al. International retrospective chart review of treatment patterns in severe FMF, TRAPS and MKD/HIDS , 2016 .
[24] I. Jéru,et al. On-demand treatment with anakinra: a treatment option for selected TRAPS patients. , 2015, Rheumatology.
[25] J. Aróstegui,et al. Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort. , 2015, Clinical and experimental rheumatology.
[26] R. Handgretinger,et al. A functional inflammasome activation assay differentiates patients with pathogenic NLRP3 mutations and symptomatic patients with low penetrance variants. , 2015 .
[27] S. Akar,et al. Efficacy of Interleukin-1 Targeting Treatments in Patients with Familial Mediterranean Fever , 2014, Inflammation.
[28] I. Touitou,et al. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry , 2013, Annals of the rheumatic diseases.
[29] M. Galeazzi,et al. From the Mediterranean to the Sea of Japan: The Transcontinental Odyssey of Autoinflammatory Diseases , 2013, BioMed research international.
[30] J. Kuemmerle-Deschner,et al. Inflammasome and cytokine blocking strategies in autoinflammatory disorders. , 2013, Clinical immunology.
[31] A. Martini,et al. The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age , 2013, Arthritis Research & Therapy.
[32] G. Merlini,et al. Amyloidosis in autoinflammatory syndromes. , 2012, Autoimmunity reviews.
[33] M. McDermott,et al. Autoinflammatory syndromes and cellular responses to stress: pathophysiology, diagnosis and new treatment perspectives. , 2012, Best practice & research. Clinical rheumatology.
[34] Jos W. M. van der Meer,et al. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases , 2012, Nature Reviews Drug Discovery.
[35] J. van der Meer,et al. On-demand anakinra treatment is effective in mevalonate kinase deficiency , 2011, Annals of the rheumatic diseases.
[36] P. Hawkins,et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes , 2011, Annals of the rheumatic diseases.
[37] D. Foell,et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. , 2011, Arthritis and rheumatism.
[38] A. Elhan,et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. , 2009, Rheumatology.
[39] D. Rigante,et al. Hydrocephalus in CINCA syndrome treated with anakinra , 2006, Child's Nervous System.
[40] E. Sohar,et al. Familial Mediterranean fever. , 1958, A.M.A. archives of internal medicine.